Compare Pfizer Inc (PFE) vs Workiva Inc (WK) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Workiva (WK) trades at $57.19, up 0.02% on the day, with a bullish technical outlook from moving averages and strong analyst support. The company shows robust revenue growth, reaching $884.57M in 2025, and has consistently beaten earnings estimates in recent quarters. Recent news highlights its AI-powered platform growth and upcoming Q2 2026 results.

The stock presents a positive outlook with an 88.89% buy rating from analysts and a consensus price target of $71.00, suggesting 24% upside. Risks include high valuation multiples (P/E 238.29) and profitability challenges, with net income margin at 1.53% for 2026. Investors should weigh growth potential against execution risks in a competitive software market.